News for Sarepta Therapeutics, Inc. (0L35.L)

On June 6, 2025, Scotiabank analyst Louise Chen upgraded the rating for Sarepta Therapeutics (SRPT) from "Sector Perform" to "Sector Outperform". This change re

Scotiabank has elevated its rating for Sarepta (SRPT) from Sector Perform to Outperform, maintaining its price target at $80. The firm believes that recent setb

Sarepta Therapeutics, Inc. (SRPT) has received a positive upgrade from Scotiabank analyst Louise Chen. The analyst elevated the stock's rating from Sector Perfo

Summary Sarepta Therapeutics Inc (SRPT), a leader in precision genetic medicine for rare diseases, announced that its rAAVrh74 viral vector, used in the investi

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks that Jim Cramer discusses. A caller asked about Sarepta Therapeutics Inc. (NASDAQ:SRPT), a biotech firm working on RNA therapies. Cramer responded […]

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc.

Sarepta Therapeutics, trading under the ticker SRPT, witnessed a 5% increase in its stock price, reaching $42.11. This uptick followed the United Kingdom's deci

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics SRPT, and it's important for retail traders to take note. \This activity came ...

Summary Sarepta Therapeutics Inc (SRPT), a leader in precision genetic medicine for rare diseases, announced that the Medicines & Healthcare products Regulatory

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandis

Market Analysis by covering: Sarepta Therapeutics Inc, Lantheus Holdings Inc, Krystal Biotech Inc. Read 's Market Analysis on Investing.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Lab

Arrowhead Pharmaceuticals Inc (ARWR) reports a significant increase in net income, showcasing robust financial health.Strategic collaboration with Sarepta Ther

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (”œSarepta” or the â

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Sarepta Therapeutics (SRPT) to present at BofA Securities Health Care Conference on May 14, 2025. Live webcast available on Sarepta's investor relations

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank’s decision to […]